Literature DB >> 18045316

Massive periosteal reaction a presenting feature of acute megakaryocytic leukemia.

Takahiro Ueda1, Yasuhiko Ito, Miho Maeda, Yoshitaka Fukunaga.   

Abstract

Acute megakaryoblastic leukemia (AML M7) is a biologically heterogeneous form of acute myeloid leukemia accounting for 14.6% of cases. In many instances in the past, AML M7 has been classified as undifferentiated leukemia, myelodysplasia, myelofibrosis or some other disease because of its complex clinical presentation or the difficulty of obtaining and interpreting bone marrow samples. However, with currently available morphological, cytochemical, cytogenetic and immunophenotypic methods, AML M7 can now be reliably diagnosed. Although the radiographic spectrum of bony changes in leukemia have been well characterized, skeletal X-ray abnormalities in the setting of AML M7 in pediatric patients have been described in few reports that were associated with bone marrow fibrosis. Here we report on a 14-month-old girl who presented with a massive periosteal reaction of the extremities and clavicles associated with myelofibrosis, a presenting feature of AML M7. The bone changes were very unusual in this case.

Entities:  

Mesh:

Year:  2007        PMID: 18045316     DOI: 10.1111/j.1442-200X.2007.02470.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  3 in total

1.  Hyperostosis - an unusual radiographic presentation of Myelodysplastic Syndrome transformed to Acute Myeloid Leukemia.

Authors:  Arie Franco; Kristopher N Lewis; Joshua M Blackmon; Elizabeth J Manaloor
Journal:  J Radiol Case Rep       Date:  2010-11-01

Review 2.  [Skeletal manifestations of systemic hematologic disorders].

Authors:  J Luitjens; A Baur-Melnyk
Journal:  Radiologe       Date:  2021-11-24       Impact factor: 0.635

3.  Skeletal scintigraphy manifestations of hematologic disorders.

Authors:  Shrikant V Solav; Ritu Bhandari; Pallavi Solav
Journal:  Indian J Nucl Med       Date:  2012-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.